title: [Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
abstract: Current guidelines for the management of hypercholesterolemia identify LDL cholesterol (LDL-c) reduction as the primary therapeutic target and have highlighted the need to use statins to achieve it. There are six statins with four different doses and with different power-reducing LDL-c. By adding ezetimibe, there are 48 therapeutic possibilities. This extensive offer provides pharmaceutical treatment, but it is difficult to choose the most cost-effective statin because it is very difficult to remember all the powers and costs of treatment options. This paper offers a method to prioritize the best cost-effective lipid lowering, and chooses the cheapest statin that achieves the desired therapeutic goal of LDL-c.
authors.affiliation: Unidad de Lípidos y Prevención Cardiovascular, Centro de Salud Pinto, Dirección Asistencial 4 SUR, SERMAS, Madrid, España. antoniodoctor@gmail.com
authors.forename: Antonio
authors.initials: A
authors.lastname: Ruiz García
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Gordillo López
authors.forename: Ezequiel
authors.initials: E
authors.lastname: Arranz Martínez
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Hermosa Hernán
mesh_terms: D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000097:blood; D003362:Cost-Benefit Analysis; D005229:Fatty Acids, Monounsaturated / Q000191:economics / Q000627:therapeutic use; D005464:Fluorobenzenes / Q000191:economics / Q000627:therapeutic use; D000077340:Fluvastatin; D006040:Goals; D006538:Heptanoic Acids / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy / Q000191:economics*; D007211:Indoles / Q000191:economics / Q000627:therapeutic use; D008148:Lovastatin / Q000191:economics / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D017035:Pravastatin / Q000191:economics / Q000627:therapeutic use; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use; D011758:Pyrroles / Q000191:economics / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use; D013030:Spain; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use
chemical_list: D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000077340:Fluvastatin; D000068718:Rosuvastatin Calcium; D008148:Lovastatin; D000069059:Atorvastatin; D019821:Simvastatin; D017035:Pravastatin